Maximizing Opportunities and Avoiding Mistakes in Triple Therapy for Hepatitis C Virus
Maximizing Opportunities and Avoiding Mistakes in Triple Therapy for Hepatitis C Virus
复制标题
DOI：
10.1053/j.gastro.2012.02.013
复制
发表时间：
2012-05-01
期刊：
影响因子：
29.4
通讯作者：
Fried, Michael W.
中科院分区：
文献类型：
--
作者：
Barritt, A. Sidney;Fried, Michael W.
最近开发的治疗基因1型丙型肝炎病毒（HCV）慢性感染的药物和创新策略已成为治疗的标准。蛋白酶抑制剂telaprevir （Incivek）和boceprevir （Victrelis）是首批获批的直接作用抗病毒（DAA）药物，还有更多的药物正在开发中。在3期试验中，这些药物与聚乙二醇干扰素和利巴韦林（三联治疗）联合使用，大大提高了首次治疗和有治疗经验的患者的持续病毒学应答率。三联疗法的疗效取决于患者的适当选择，尽管接受三联疗法的患者群体可以随着风险/收益比的提高而扩大。注意反映护理标准的细节，如适当的剂量、对不良反应的预期和严格遵守停药规则，将确保这些药物的成功，并为新的联合疗法开辟道路。
Recently developed drugs and innovative strategies for the treatment of chronic infection with genotype 1 hepatitis C virus (HCV) have become the standard of care. The protease inhibitors telaprevir (Incivek) and boceprevir (Victrelis) are the first direct-acting antiviral (DAA) agents approved, and many more are being developed. These drugs substantially increased rates of sustained virologic response in treatment-naive and -experienced patients, in conjunction with peginterferon and ribavirin (triple therapy), in phase 3 trials. The efficacy of triple therapy depends on appropriate selection of patients, although the population of patients that receive triple therapy could be expanded as the risk/benefit ratio improves. Attention to details that reflect the standard of care, such as appropriate dosing, anticipation of adverse effects, and strict adherence to stopping rules, will insure the success of these drugs and lead the way for new combination therapies.